145202-66-0CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1JPRXYLQNJJVCMZ-UHFFFAOYSA-NRizatriptan benzoate is a member of tryptamines.
145202-66-0DTXSID20162937FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H302 (35.6%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P304+P340, P305+P351+P338, P318, P319, P330, P337+P317, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 149 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Rizatriptan benzoate
vLess-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
RIZATRIPTAN BENZOATE
Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]; Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]
RIZATRIPTAN BENZOATE ODT
Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]; Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]
DescriptionKnown as a 5-hydroxytryptamine agonist, Rizatriptan Benzoate is the benzoate salt form of rizatriptan with anti-migraine activity, which can be used to treat the migraine headaches. It is FDA-approved to use in the treatment of acute migraine attacks with or without aura, especially taken at the first sign of a migraine headache. However, it cannot prevent future migraine attacks and it is ineffective to prevent other types of headache. The pain of migraine headaches is believed to be induced by dilated blood vessels inside the head. Rizatriptan Benzoate relieves the pain by inducing vasoconstriction, which functions as an agonist at serotonin 5-HT1B and 5-HT1D receptors. The selective receptor binding is effective to constrict cranial vessels and inhibit the transmission of nociception, thus providing relief of migraine headaches.
DescriptionRizatriptan was launched for the first time as Maxalt in Mexico for the acute treatment of migraine headaches with or without aura in adults. It is the third in a new generation of triptan migraine drugs to challenge the firstgeneration product Sumatriptan from Glaxo Wellcome, after Zolmitriptan (Zeneca) and Naratriptan (Glaxo Wellcome). It can be synthetically obtained by two related routes having respectively 3 and 4 steps, both starting from 1 -(4-aminobenzyl)-l,2,4-triazole. Rizatriptan is a full 5-HT1D/1B receptor agonist retaining a significant affinity at 5-HT1A sites (pIC50 = 6.4), with a low affinity for nond-HT sites. It shows craniovascufar selectivity for human isolated middle meningeal over coronary arteries ; its effect on coronary artery constriction is significantly less than that for Sumatriptan. Rizatriptan inhibits the release of neuropeptides that cause swelling of cranial blood vessels. Rizatriptan has a good oral bioavailability (64% and 47% in rats and dogs respectively). and a rapid onset of action : the headache relief in human occurs within 30 to 45 minutes of taking 20 mg. It also relieved nausea and hypersensitivity to noise (phonophobia) and light (photophobia) that are often symptoms accompanying a migraine attack. Among at least 6 metabolites identified in humans after a single oral dose (60 mg), the major urinary metabolite was the corresponding indole-3-acetic acid. Maxalt is available as a novel oral formulation of rapidly dissolving tablets or wafers that does not require liquid for ingestion.
CHEMBL1201032CHEBI:8875UsesRizatriptan Benzoate is a selective serotonin 5-HTID receptor agonist and used to treat migraine (1,2,3). It is structurally derived from tryptamine.
UsesRizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches. It is believed to work by narrowing the blood vessels around the brain. Rizatriptan also reduces the substances in the body, which can also reduce headac
UsesA selective serotonin 5-HTID receptor agonist. Structurally derived from tryptamine
General DescriptionPharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
DefinitionChEBI: Rizatriptan benzoate is a member of tryptamines.